Last reviewed · How we verify
Active JNJ Drug
Active JNJ drug is a monoclonal antibody that targets a specific molecular target.
Active JNJ drug is a monoclonal antibody that targets a specific molecular target. Used for Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | Active JNJ Drug |
|---|---|
| Also known as | JNJ-39393406 |
| Sponsor | Chengappa, K.N. Roy, MD |
| Drug class | Monoclonal antibody |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action is not well understood, but it is believed to work by binding to a specific receptor and inhibiting its activity.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
Key clinical trials
- Novel Smoking Cessation Drug for Schizophrenia (PHASE2)
- A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis (PHASE2)
- Test of Novel Drug for Smoking Cessation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active JNJ Drug CI brief — competitive landscape report
- Active JNJ Drug updates RSS · CI watch RSS
- Chengappa, K.N. Roy, MD portfolio CI